Inventor · disambiguated record
David Bogucki
Also filed as: BOGUCKI DAVID · BOGUCKI DAVID E · BOGUCKI DAVID EARL
32 granted patents·12 pending applications·495 citations·filing 1998–2024
97Inventor score
Top patents by PatentIndex Score
44 records- 0194US7709486B2CXCR4 antagonistsGENZYME CORP·Filed 2008·Granted May 4, 2010·20 cites·6 claims
- 0294US7354934B2Chemokine receptor binding heterocyclic compounds with enhanced efficacyANORMED INC·Filed 2005·Granted Apr 8, 2008·34 cites·10 claims
- 0394US6864265B2Chemokine receptor binding heterocyclic compoundsANORMED INC·Filed 2001·Granted Mar 8, 2005·42 cites·6 claims
- 0494US6750348B1Chemokine receptor binding heterocyclic compoundsANORMED INC·Filed 2000·Granted Jun 15, 2004·61 cites·30 claims
- 0593US7091217B2Chemokine receptor binding heterocyclic compoundsANORMED INC·Filed 2004·Granted Aug 15, 2006·31 cites·12 claims
- 0693US6835731B2Chemokine receptor binding heterocyclic compoundsANORMED INC·Filed 2001·Granted Dec 28, 2004·53 cites·10 claims
- 0793US6734191B2Chemokine receptor binding heterocyclic compoundsANORMED INC·Filed 2001·Granted May 11, 2004·35 cites·15 claims
- 0890US11174268B2Benzenesulfonamide compouds and their use as therapeutic agentsXENON PHARMACEUTICALS INC·Filed 2020·Granted Nov 16, 2021·2 cites·25 claims
- 0990US7354932B2Chemokine receptor binding heterocyclic compounds with enhanced efficacyANORMED INC·Filed 2003·Granted Apr 8, 2008·27 cites·21 claims
- 1089US8778967B2Chemokine receptor binding heterocyclic compounds with enhanced efficacyBRIDGER GARY·Filed 2012·Granted Jul 15, 2014·18 cites·20 claims
- 1189US6756391B2Antiviral compoundsANORMED INC·Filed 2002·Granted Jun 29, 2004·23 cites·7 claims
- 1288US9765085B2SHIP1 modulators and methods related theretoAQUINOX PHARMACEUTICALS (CANADA) INC·Filed 2014·Granted Sep 19, 2017·12 cites·8 claims
- 1388US7414065B2Methods to modulate conditions mediated by the CXCR4 receptorGENZYME CORP·Filed 2004·Granted Aug 19, 2008·20 cites·8 claims
- 1488US7160872B2Methods to treat conditions mediated by chemokine receptorsANORMED INC·Filed 2004·Granted Jan 9, 2007·20 cites·12 claims
- 1588US6506770B1Antiviral compoundsANORMED INC·Filed 1998·Granted Jan 14, 2003·53 cites·7 claims
- 1684US6667320B2Chemokine receptor binding heterocyclic compoundsANORMED·Filed 2000·Granted Dec 23, 2003·17 cites·19 claims
- 1782US9540353B2SHIP1 modulators and methods related theretoAQUINOX PHARMACEUTICALS (CANADA) INC·Filed 2014·Granted Jan 10, 2017·6 cites·19 claims
- 1876US7396840B2Chemokine receptor binding heterocyclic compoundsGENZYME CORP·Filed 2006·Granted Jul 8, 2008·1 cites·9 claims
- 1975US10322111B2Chemokine receptor binding heterocyclic compounds with enhanced efficacyGENZYME CORP·Filed 2016·Granted Jun 18, 2019·1 cites·13 claims
- 2075US7312234B2Chemokine receptor binding heterocyclic compoundsANORMED·Filed 2004·Granted Dec 25, 2007·7 cites·6 claims
- 2173US7629337B2Chemokine receptor binding heterocyclic compoundsGENZYME CORP·Filed 2006·Granted Dec 8, 2009·1 cites·9 claims
- 2270US10100056B2SHIP1 modulators and methods related theretoAQUINOX PHARMACEUTICALS CANADA INC·Filed 2014·Granted Oct 16, 2018·1 cites·7 claims
- 2369US7084155B2Chemokine receptor binding heterocyclic compoundsANORMED·Filed 2004·Granted Aug 1, 2006·3 cites·15 claims
- 2468US7022717B2Chemokine receptor binding heterocyclic compoundsANORMED INC·Filed 2003·Granted Apr 4, 2006·2 cites·11 claims
- 2567US7183273B2Chemokine receptor binding heterocyclic compoundsANORMED INC·Filed 2004·Granted Feb 27, 2007·2 cites·10 claims
- 2667US2020000774A1Chemokine receptor binding heterocyclic compounds with enhanced efficacyGENZYME CORP·Filed 2019·Application pending·0 cites
- 2766US7491735B2Chemokine receptor binding compoundsGENZYME CORP·Filed 2004·Granted Feb 17, 2009·3 cites·6 claims
- 2863US2015038509A1Chemokine Receptor Binding Heterocyclic Compounds With Enhanced EfficacyGENZYME CORP·Filed 2014·Application pending·0 cites
- 2962US7807694B2Chemokine receptor binding heterocyclic compoundsGENZYME CORP·Filed 2006·Granted Oct 5, 2010·0 cites·4 claims
- 3062US2008167341A1Chemokine receptor binding heterocyclic compounds with enhanced efficacyBRIDGER GARY·Filed 2008·Application pending·0 cites
- 3161US2010105915A1Chemokine receptor binding heterocyclic compoundsBRIDGER GARY J·Filed 2009·Application pending·0 cites
- 3260US2007060591A1Chemokine receptor binding heterocyclic compoundsBRIDGER GARY J·Filed 2006·Application pending·0 cites
- 3359US2022409589A1Chemokine receptor binding heterocyclic compounds with enhanced efficacyGENZYME CORP·Filed 2022·Application pending·0 cites
- 3458US2006069129A1Chemokine receptor binding heterocyclic compoundsBRIDGER GARY J·Filed 2005·Application pending·0 cites
- 3557US2008090846A1Chemokine receptor binding heterocyclic compoundsBRIDGER GARY·Filed 2007·Application pending·0 cites
- 3653US10272081B2SHIP1 modulators and methods related theretoAQUINOX PHARMACEUTICALS CANADA INC·Filed 2018·Granted Apr 30, 2019·0 cites·2 claims
- 3752US12378231B2Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereofAPOGEE PHARMACEUTICALS INC·Filed 2024·Granted Aug 5, 2025·0 cites·27 claims
- 3851US2019023709A1Ship1 modulators and methods related theretoAQUINOX PHARMACEUTICALS CANADA INC·Filed 2018·Application pending·0 cites
- 3950US9937167B2SHIP1 modulators and methods related theretoAQUINOX PHARMACEUTICALS CANADA INC·Filed 2016·Granted Apr 10, 2018·0 cites·20 claims
- 4049US10174046B2SHIP1 modulators and methods related theretoAQUINOX PHARMACEUTICALS CANADA INC·Filed 2017·Granted Jan 8, 2019·0 cites·11 claims
- 4149US2003220341A1Chemokine receptor binding heterocyclic compounds with enhanced efficacyFiled 2002·Application pending·0 cites
- 4247US2018162868A1Benzenesulfonamide compounds and their use as therapeutic agentsXENON PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 4344US7498346B2Chemokine receptor binding compoundsGENZYME CORP·Filed 2005·Granted Mar 3, 2009·0 cites·12 claims
- 4440US2022339150A1Endocannabinoid system-targeting prodrugs and therapeutic uses thereofMEDIPURE PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →